Clinical Intelligence Landscape
Indication: Type 2 Diabetes (EFO_0001360)
Evaluating targets: GLP1R (Established), GIPR (Emerging), SGLT2 (Established), SLC30A8 (Genetic Whitespace).
Drug Pipeline by Phase
Shows the number of drugs currently in development or approved. Notice the stark "whitespace" for SLC30A8.
Target Evidence Scores
Strength of association between target and T2D. SLC30A8 has maximum genetic evidence but zero drug evidence.
Key Drugs in Pipeline
| Target |
Drug Name |
Highest Phase |
Mechanism of Action |